SMS Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SMS Pharmaceuticals reported strong full-year results for FY2026. Standalone revenue from operations grew 13.3% to Rs. 88,687 lakhs from Rs. 78,275 lakhs. Net profit after tax surged 28.1% to Rs. 8,761 lakhs versus Rs. 6,838 lakhs in the prior year. On a consolidated basis, net profit jumped ~47.5% to Rs. 10,199 lakhs, helped significantly by its 34.83% associate VKT Pharma contributing Rs. 1,399 lakhs to consolidated PAT. The company recommended a final dividend of Rs. 0.40 per share (40%) for FY2026. Statutory auditors Suryanarayana & Suresh issued an 'Unmodified Opinion' with no qualifications. The company also filed a statement of deviation/variation under Regulation 32 regarding fund utilisation from a preferential issue. Share warrants conversion added Rs. 4,762.50 lakhs to equity.
The 28%+ PAT growth and clean audit report are positive signals for shareholders. However, investors should note the significant working capital pressure with inventories rising sharply and operating cash flow declining year-on-year.